Actively Recruiting
Study of Liver Response to Oral Glucose and Semaglutide Treatment in Adults with Non-Alcoholic Fatty Liver Disease and Healthy Volunteers
Led by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Updated on 2026-10-27
104
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Non-alcoholic fatty liver disease NAFLD, including its progressive form non-alcoholic steatohepatitis NASH, causes fat buildup and damage in the liver. This study investigates how the liver responds to an oral glucose load in people with NAFLD and healthy volunteers. It also aims to find baseline factors that predict how patients with NAFLD respond to treatment with the drug semaglutide, a type of GLP-1 receptor agonist, to better understand disease mechanisms and treatment effects. Participants include adults with steatosis or NASH and healthy volunteers. After screening, participants undergo multiple assessments including biopsies, imaging, and blood tests. Those with NAFLD receive semaglutide injections once weekly at home for 30 weeks, with clinic visits at weeks 1, 2, 4, 8, 12, 16, 20, and 24. Testing occurs at baseline, during treatment, and after a 12-week treatment stop period. Throughout the study, participants have blood, urine, heart, and imaging tests, as well as liver and fatty tissue biopsies for NAFLD patients. Researchers monitor liver gene expression, clinical and histological improvements, and liver fat content. Healthy volunteers conclude participation after baseline testing. The total study duration including treatment and follow-up is about 42 weeks, with close monitoring of liver response and treatment effects.
CONDITIONS
Brief Title
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Research Team
Y
Yaron Rotman, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here